In @entity1 with @entity11810 , histomorphometric studies reported both increased resorption and decreased remodeling. We aimed at examine bone remodeling in these @entity1 by biological marker measurement. We compared pre-treatment carboxy-terminal cross-linking telopeptide of type I collagen ( @entity4740 ) and bone alkaline phosphatase (bALP) levels in 49 @entity1 , mean age 59    14 year, with @entity11810 with @entity174 (40 @entity1 ) or @entity170 diagnosed by densitometry (9 @entity1 ) with 50 age-matched controls. The influence of baseline remodeling level on @entity561 efficacy was studied. Bone remodeling markers ( @entity4740 and bALP) did not significantly differ between @entity1 and controls and were correlated in both groups. There was no correlation between these markers, @entity560 and @entity461 levels. Twenty-one @entity1 underwent repeat densitometry after 1 year of @entity561 (70 mg/week). Mean annual BMD increase, spine +4.1    3.9%, and hip +1.5    1.2% showed no correlation with baseline @entity4740 . Bone remodeling is very heterogeneous and formation and resorption remain biologically coupled in both @entity3930 and controls. Baseline remodeling level does not affect the action of @entity561 on BMD.

Heterogeneity of biological bone markers in XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'men'] @entity3930 :: ('MESH:D005834', 'Disease') :: ['idiopathic male osteoporosis'] @entity11810 :: ('MESH:C537700', 'Disease') :: ['idiopathic osteoporosis'] @entity174 :: ('MESH:D050723', 'Disease') :: ['fractures'] @entity561 :: ('MESH:D019386', 'Chemical') :: ['alendronate'] @entity170 :: ('MESH:D010024', 'Disease') :: ['osteoporosis'] @entity461 :: ('5741', 'Gene') :: ['PTH'] @entity4740 :: ('MESH:D019294', 'Disease') :: ['CTX'] @entity560 :: ('MESH:D014807', 'Chemical') :: ['vitamin D']
@entity3930 :: (MESH:D005834,Disease) :: ['idiopathic male osteoporosis']
